No trading action warranted; monitor future Form 4 filings for actual buying or selling activity by Bienaime or other insiders, which could signal sentiment shifts
Price Chart
Executive Summary
Jean-Jacques Bienaime, a director or significant insider of Ascendis Pharma, filed a Form 3 to report initial beneficial ownership of 9,160 ordinary shares and 172.35 warrants exercisable into shares, with a power of attorney granted to several executives to file SEC reports on his behalf. This is a routine initial filing for ownership disclosure and does not indicate any change in holdings or strategic direction.
Key Facts
- Jean-Jacques Bienaime filed Form 3 to report initial beneficial ownership as of March 23, 2026
- He holds 9,160 ordinary shares (including ADSs) and 172.35 warrants
- Warrants vest 25% on June 10, 2026, then in 36 equal monthly installments through 2035
- Power of attorney granted to six company executives, including CEO, CFO, and CLO, to file SEC forms on his behalf
- Filing is administrative and related to compliance, not a transaction or material event
Financial Impact
No immediate financial impact — ownership levels are small (9,160 shares in a $14.2B company) and no transactions reported
Risk Factors
- Minimal risk — this is a standard disclosure with no operational or financial implications
- Potential misinterpretation of warrant vesting schedule as near-term dilution, though amounts are negligible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001610717-26-000138 |
| Document: 0001610717-26-000138-index-headers.html | 0001610717-26-000138 |
| Document: 0001610717-26-000138-index.html | 0001610717-26-000138 |
| Document: 0001610717-26-000138.txt | 0001610717-26-000138 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access